Breakthrough Cancer Trials Target Deadliest Tumors with Precision Medicine

Ingelheim, Monday, 22 June 2026.
Boehringer Ingelheim just launched three Phase III trials for aggressive cancers with few treatment options, including lung and neuroendocrine tumors. The most striking fact? One trial tests a drug already approved in the U.S. and Asia for HER2-mutant lung cancer, now being studied in earlier-stage patients to potentially stop recurrence after surgery. This marks a major push in precision oncology, where therapies are tailored to tumor biology rather than a one-size-fits-all approach.